Immune Therapeutics, Inc., Appoints Two New Board Members

ORLANDO, Fla., March 3, 2016, IMUN, /PRNewswire/  Immune Therapeutics, Inc. (OTC:BB IMUN), a specialty pharmaceutical company involved in the manufacture, commercialization, distribution and marketing of novel, patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body s immune system, today announced the appointment of two new members to its Board of Directors: Clifford A. Selsky, Ph.D., MD, and Paul Akin. Paul Akin and Dr. Selsky s breadth of knowledge and experience will provide invaluable insight to Immune as we continue to grow the business and strive to deliver innovative therapies in emerging nations, said Noreen Griffin, CEO. I m pleased to welcome both Paul Akin and Dr. Clifford Selsky to the board. Paul brings an extraordinary depth of financial experience developed across his operating and board roles, while Dr. Selsky brings critical perspective as a scientist, physician and patient advocate, said Chris Pearce COO. Pa

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: